SMITHKLINE CLAIMS MYLAN CIMETIDINE INFRINGES TAGAMET TRADE DRESS
SMITHKLINE CLAIMS MYLAN CIMETIDINE INFRINGES TAGAMET TRADE DRESS in that Mylan has copied the color and appearance of the SmithKline Beecham ulcer drug with an aim to "delude and confuse the public into believing that its cimetidine tablets are produced by SmithKline," or are connected with the firm in some way, SB charges in a patent, trademark and trade dress law suit filed in Philadelphia federal court May 6. The suit notes that Tagamet is "a unique pale or light green color, which is not the natural color of cimetidine." Mylan's generic cimetidine tablets not only copy the color of Tagamet, SB charges, but are also "colorable imitations" of the appearance of Tagamet because of the similar shapes of the different dosage strengths.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth